Indian Journal of Pharmacy and Pharmacology

Print ISSN: 2393-9079

Online ISSN: 2393-9087

CODEN : IJPPTK

Indian Journal of Pharmacy and Pharmacology (IJPP) open access, peer-reviewed quarterly journal publishing since 2014 and is published under auspices of the Innovative Education and Scientific Research Foundation (IESRF), aim to uplift researchers, scholars, academicians, and professionals in all academic and scientific disciplines. IESRF is dedicated to the transfer of technology and research by publishing scientific journals, research content, providing professional’s membership, and conducting conferences, seminars, and award programs. With more...

  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 118

PDF Downloaded: 38


Get Permission Gunjegaonkar, Sasane, Shaikh, Joshi, and Sapkale: Cefotaxime-induced allergic reaction in a 4 years old boy: Case presentation and management strategies


Introduction

Cefotaxime, a third-generation cephalosporin, is a widely utilized semisynthetic antibiotic derived from cephalosporin-C, a substance produced by the fungus Cephalosporium.1 This antibiotic shares a structural relationship with penicillins, characterized by a dihydrothiazine ring joined to a β-lactam ring.1, 2 The development of cefotaxime involved modifications at positions 3 and 7 of these rings, resulting in various semisynthetic compounds with distinct pharmacokinetic properties and ranges of antimicrobial activity.1 Cefotaxime demonstrates high efficacy against aerobic gram-negative bacteria, including species such as Escherichia coli, Klebsiella, and Enterobacter, as well as some gram-positive bacteria like Streptococcus pneumoniae.1, 3 However, it is ineffective against anaerobes, including Pseudomonas aeruginosa and Staphylococcus aureus.1 Clinically, cefotaxime is indicated for the treatment of severe infections, particularly in immunocompromised patients. It is used to manage septicemias, hospital-acquired infections, and meningitis caused by gram-negative bacteria.2 Cefotaxime can achieve significant cerebrospinal fluid (CSF) concentrations and is effective in treating bacterial meningitis.2 Despite its broad-spectrum efficacy and general safety, cefotaxime, like other antibiotics, can cause adverse drug reactions (ADRs). These reactions range from mild gastrointestinal disturbances to severe hypersensitivity.4 Hypersensitivity reactions to cephalosporins are relatively rare but can be life-threatening if not promptly identified and managed.1, 2 The potential for such reactions necessitates careful monitoring, especially in pediatric patients, who may be more susceptible to ADRs due to their developing physiology and immune systems.4 This case report documents a hypersensitivity reaction to cefotaxime in a 4-year-old boy. The boy presented with a high-grade fever and was initially diagnosed with AFI. After being treated with cefotaxime, he developed a severe hypersensitivity reaction. This report details the clinical presentation, diagnostic workup, and management strategies employed in this case, aiming to provide insights into identifying and treating ADRs associated with cefotaxime.2, 3, 5 Understanding the mechanisms and manifestations of drug hypersensitivity reactions is critical for clinicians to ensure patient safety. Early recognition and appropriate management of these reactions can prevent complications and improve clinical outcomes. This case underscores the importance of vigilance in monitoring ADRs and highlights the need for effective communication between healthcare providers and caregivers in managing paediatric patients.2, 4 The findings from this case report contribute to the broader knowledge base on antibiotic-induced hypersensitivity reactions and their management in paediatric practice.2, 6

Case Report

Study design

The case report design is a descriptive study focusing on a single patient case.6 The case was reported at the District Civil Hospital, Osmanabad, Maharashtra, India. A clinical assessment like clinical history collection, including presenting symptoms, duration, physical examination findings, vital signs, and initial laboratory investigations (complete blood count, C-reactive protein, urine analysis, Widal test, Dengue test, etc.) was obtained from the hospital database. In the present case, the subject is a minor the oral consent was obtained from a legally acceptable person (The subject's mother). The study adheres to ethical guidelines for reporting patient information and maintained confidentiality. Cefatoxime-associated ADR is based on the application of classification systems (Rawlins-Thompson and DoTS) to categorize the hypersensitivity reaction.7

Case details

A 4-year-old boy weighing 15 kg was admitted to the outpatient department (OPD) at the Government Civil Hospital in Osmanabad with a high-grade fever of 110ºF persisting for 4-5 days. Additional symptoms reported by the caretaker included a cold, loss of appetite and general weakness over the same period. There was no history of vomiting. Following an initial consultation with a physician, the boy was admitted to the paediatric department with a provisional diagnosis of AFI.

Initial treatment regimen

On the first day of admission, the following treatment regimen was initiated with parenteral cefotaxime 750mg administered BD; Injection of Paracetamol 200 mg administered OD; Injection of Febrinil 75mg administered immediately upon admission; Paracetamol syrup 250 mg/5 ml administered every 6 hours to manage fever.

Investigations and reports

The following diagnostic tests were advised to identify the underlying cause of the AFI Complete Blood Count (CBC); C-reactive protein (CRP); Urine Analysis; Widal Test and Dengue Test. On the second day, the test results were as follows Widal Test Positive for antigen O++; C-Reactive Protein (CRP) Elevated at 1.86 mg/dl (Reference value: <1 mg/dl); Dengue Test Negative, Urine Albumin and Urine Sugar Nil; No Abnormality Detected (NAD) in Urine Microscopic Examination (ME); Complete Blood Count (CBC) includes White Blood Cells (WBC) 8.62 × 109/L; Hemoglobin (Hb) 11.6 mmol/L; Platelets 246 × 109/L [Table 1].

Table 1

Diagnostic test results and clinical significance

Diagnostic Test

Result

Reference Value

Clinical Significance

Widal Test

Positive for antigen O++

-

Suggests possible typhoid fever or enteric fever; further investigation is needed for confirmation8

C-reactive protein (CRP)

Elevated at 1.86 mg/dL

<1 mg/dL

Indicates inflammation or infection; elevated levels support the presence of an acute inflammatory response9

Dengue Test

Negative

-

Rules out dengue fever as the cause of illness10

Urine Analysis

Urine Albumin: Nil

-

No proteinuria was detected; which suggests the absence of nephrotic syndrome or significant renal involvement11

Urine Sugar: Nil

-

No glucosuria was detected; which rules out diabetes mellitus or significant renal glucose loss12

Urine Microscopic Examination

No Abnormality Detected (NAD)

-

No signs of urinary tract infection or other abnormalities13

Complete Blood Count (CBC)

White Blood Cells (WBC): 8.62 × 10^9/L

4.0-11.0 × 10^9/L

Within normal range; indicates no significant leukocytosis or leukopenia14

Hemoglobin (Hb): 11.6 mmol/L

11.0-13.5 mmol/L (for children)

Within normal range for age; no evidence of anaemia

Platelets: 246 × 10^9/L

150-450 × 10^9/L

Within normal range; suggests no significant thrombocytopenia or thrombocytosis

Clinical Course

On the second day of cefotaxime therapy, the patient developed a generalized rash characterized by erythematous, maculopapular lesions, indicating a hypersensitivity reaction to cefotaxime [Fig 1]. His temperature was recorded at 99ºF. Immediate action was taken to discontinue cefotaxime.

Figure 1

Image showing to allergic reaction to cefotaxime on face, legs, and stomach

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/5ab7d9bb-0b7d-45cf-b494-3bd87fad26d0/image/6294e8d8-a01d-4a56-b25b-6e913ec3c803-ufig-1-30th-august-2024.jpg

Management of hypersensitivity reaction

Injection Avil (Pheniramine Maleate) 5.6875mg/0.5 mL was administered, with an injection of hydrocortisone 75 mg, to manage the hypersensitivity reaction. Following the discontinuation of cefotaxime due to the adverse reaction, the treatment regimen was adjusted to include intravenous Amikacin 100 mg administered BD.

Table 2

Reported case studies of cefotaxime in children

Hypersensitivity Reaction

Case Description

Dose and Duration

Country

Ref

Anaphylaxis

A 5-year-old boy experienced anaphylactic shock within minutes of receiving cefotaxime for an ear infection, showing symptoms such as respiratory distress, hypotension, and generalized swelling.

Dose: 100 mg/kg/day, Duration: Single dose

Turkey

5

Maculopapular Rash

A 7-year-old girl developed a diffuse maculopapular rash three days after starting cefotaxime for a respiratory tract infection, which resolved upon discontinuation of the antibiotic.

Dose: 50 mg/kg/day, Duration: 3 days

India

6

Toxic Epidermal Necrolysis (TEN)

A 12-year-old girl presented with TEN, characterized by widespread skin detachment and necrosis, two weeks after cefotaxime treatment for sepsis, necessitating intensive care and supportive treatment.

Dose: 100 mg/kg/day, Duration: 14 days

Belgium

15

Stevens-Johnson Syndrome (SJS)

A 10-year-old boy developed SJS with extensive mucocutaneous involvement, including blistering and peeling of skin, within a week of cefotaxime administration for a bacterial infection.

Dose: 80 mg/kg/day, Duration: 7 days

India

2

Serum Sickness-like Reaction

An 8-year-old boy developed a fever, rash, and joint pain ten days after starting cefotaxime for a urinary tract infection, with symptoms resolving after stopping the medication and administering steroids.

Dose: 50 mg/kg/day, Duration: 10 days

USA

16

Eosinophilia

A 6-year-old girl developed marked eosinophilia two weeks after beginning cefotaxime for pneumonia, which resolved following cessation of the drug.

Dose: 60 mg/kg/day, Duration: 14 days

Italy

3

Discussion

Adverse drug reactions (ADRs) pose significant challenges in clinical practice, ranging from mild discomfort to life-threatening conditions. Understanding and categorizing these reactions are crucial for effective pharmacovigilance and patient safety. The Rawlins-Thompson and DoTS classification systems offer distinct approaches to classifying and analyzing ADRs, providing valuable frameworks for clinicians and researchers. The Rawlins-Thompson system, established in 1981, divides ADRs into two main types. Type A (Augmented) reactions result from the known pharmacological actions of the drug. They are dose-dependent and occur in a quantitatively exaggerated manner. Type A reactions are often predictable and more common.17 Type B (Bizarre) reactions are unpredictable and idiosyncratic. They are qualitatively abnormal and appear unrelated to the drug's pharmacology. Type B reactions tend to be more serious, with a higher risk of fatalities. The DoTS classification system focuses on three key factors that influence the occurrence and manifestation of ADRs. Dose-relatedness examines whether the adverse reaction correlates with the dose of the administered drug. Certain reactions, such as nephrotoxicity from aminoglycosides, exhibit clear dose-related patterns.18, 19 Timing considers the temporal relationship between drug administration and the onset of the adverse reaction. Immediate reactions (e.g., anaphylaxis shortly after drug infusion) highlight acute timing-related ADRs. Susceptibility factors in individual patient characteristics that predispose them to adverse reactions. Age, genetic predisposition, underlying diseases, and concomitant medications can influence susceptibility.15 The DoTS framework provides a comprehensive approach to analyzing ADRs beyond the drug's inherent properties, incorporating the dynamic interaction between drug exposure, timing of onset, and patient-specific factors. In the case of cefotaxime, a third-generation cephalosporin widely used for its efficacy against gram-negative bacteria, adverse reactions can vary from mild gastrointestinal upset to severe hypersensitivity reactions.13, 14 The DoTS system allows clinicians and researchers to classify these reactions based on Dose-Relatedness: While cefotaxime is generally well-tolerated, hypersensitivity reactions such as those observed in pediatric patients can be dose-independent and unpredictable.13, 15 Timing: Hypersensitivity reactions typically manifest within hours to days after drug exposure, emphasizing acute timing-related ADRs in clinical settings. Susceptibility: Pediatric patients, due to their developing immune systems, may exhibit increased susceptibility to hypersensitivity reactions, necessitating careful monitoring and management.2, 10 The Rawlins-Thompson and DoTS classification systems complement each other in providing a comprehensive understanding of ADRs associated with cefotaxime and other drugs. While Rawlins-Thompson categorizes reactions based on pharmacological mechanisms, DoTS offers a nuanced approach considering dose, timing, and patient susceptibility.6, 20 This integrated approach enhances pharmacovigilance efforts, facilitates targeted interventions, and improves patient outcomes by mitigating risks associated with ADRs. Future research should focus on refining these frameworks, incorporating genomic and biomarker data to enhance predictive capabilities and personalized medicine approaches in ADR management.21

Conclusion

This case underscores clinicians' need to remain vigilant for ADRs, even with widely used and generally safe antibiotics like cefotaxime. Prompt recognition and management of hypersensitivity reactions are crucial to prevent further complications and ensure patient safety. Discontinuation of the offending agent and appropriate supportive care are essential steps in managing such reactions. In pediatric patients, the potential for hypersensitivity reactions requires careful monitoring and communication between healthcare providers and caregivers. This case also highlights the utility of classification systems like Rawlins-Thompson and DoTS in understanding and managing ADRs. Clinicians should know these frameworks to anticipate better, identify, and address adverse reactions in their practice. Ultimately, this case contributes to the broader knowledge base on antibiotic-induced hypersensitivity reactions and their management in pediatric practice. It emphasizes the need for ongoing research and education to enhance the safety and effectiveness of antibiotic therapy in children.

Limitations of Case Study

The report is based on a single patient, making it difficult to generalize the findings to a broader population. The specific case may not reflect typical responses or hypersensitivity reactions in other patients. The case does not mention long-term follow-up, leaving uncertainty regarding the patient’s recovery and whether there were any delayed reactions or complications following the hypersensitivity episode. Further diagnostic testing, such as skin testing or drug provocation tests, is absent. The report does not explore specific patient factors that may have predisposed the child to an ADR, such as genetic markers, atopy, or prior exposure to cephalosporins or beta-lactam antibiotics.

Source of Funding

None.

Conflict of Interest

None.

Acknowledgment

The authors are thankful to the Management and Principal ASPM’s K. T. Patil College of Pharmacy. The author also acknowledges the help and support provided by District Civil Hospital Authorities, Osmanabad. Case patient and his parents.

References

1 

DF Mcneeley AE Brown GJ Noel M Chung H De Lencastre An investigation of vancomycin-resistant Enterococcus faecium within the pediatric service of a large urban medical centerPediatr Infect Dis J19981731848

2 

PN Goldwater Cefotaxime and ceftriaxone cerebrospinal fluid levels during treatment of bacterial meningitis in childrenInt J Antimicrob Agents200526540811

3 

K Mansour NB Fadhel NB Fredj HB Romdhane A Chaabane Z Chadli Cefotaxime-induced drug reaction with eosinophilia and systemic symptom in a child with cross-reactivity to other cephalosporins and cosensitization to teicoplaninBr J Clin Pharmacol202389254450

4 

IS Padda S Nagalli. Cefotaxime2024Statpearls Publishinghttps://www.ncbi.nlm.nih.gov/books/NBK560653/

5 

BS Krishnan KM Jaiswal S Dudhgaonkar LB Raghute Anaphylactic reaction following injection cefotaxime sodiumJ Pharmacol Pharmacother20211211379

6 

S Bellary B Krishnankutty MS Latha Basics of case report form designing in clinical researchPerspect Clin Res20145415966

7 

B Matijević Đ Delalić D Meštrović M Petrinović J Jug I Prkačin Side-effects of medications in emergency medicineCardiol Croat175-696101

8 

RW Peeling H Artsob JL Pelegrino P Buchy MJ Cardosa S Devi Evaluation of diagnostic tests: DengueNat Rev Microbiol20108S307

9 

S Noorbakhsh S Rimaz AA Rahbarimanesh S Mamishi Interpretation of the Widal test in infected childrenIranian Journal of Public Health2003321357

10 

K Hod T Ringel-Kulka CF Martin N Maharshak Y Ringel High-sensitive C-reactive protein as a marker for inflammation in irritable bowel syndromeJ Clin Gastroenterol201650322732

11 

A Marra A Bondesan D Caroli A Sartorio Complete blood count (cbc)-derived inflammation indexes are useful in predicting metabolic syndrome in adults with severe obesityJ Clin Med20241351353

12 

Y Cao L Shao M Xin Y Zhang Y Xu Y Song Urine protein in patients with type I hypersensitivity is indicative of reversible renal tube injuryLife Sci2022305120735

13 

K Haq DM Patel Urinalysis: Interpretation and clinical correlationsMed Clin North Am2023107465979

14 

AP Singh R Saxena S Saxena Cytopathology: An Important aspect of medical diagnosisJ Oncol Hematol2023123

15 

TA Babu V Sharmila Cefotaxime-induced near-fatal anaphylaxis in a neonate: A case report and review of literatureIndian J Pharmacol20114356112

16 

S Lahiry D Mukherjee Cefotaxime-induced Stevens-Johnson syndromeAsian J Med Sci201676

17 

MD Rawlins JW Thompson DM Davies Pathogenesis of adverse drug ­reactionsTextbook of adverse drug reactionsOxford University Press1977

18 

IR Edwards JK Aronson Adverse drug reactions: Definitions, diagnosis, and managementLancet2000356923712559

19 

M Pirmohamed S James S Meakin C Green AK Scott TJ Walley Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18820 patientsBMJ20043297456159

20 

J Jose AR Cox V Paudyal Pharmacovigilance and Drug Safety: A Practical GuideSpringer

21 

BK Babu Personalized medicine and advancements in pharmacology: shaping the future of healthcareInt J Pharm Investig202414233842



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Article type

Case Report


Article page

168-172


Authors Details

Shivshankar M Gunjegaonkar, Diksha Raosaheb Sasane, Sohail Allibaba Shaikh, Amol A Joshi, Geeta N Sapkale


Article History

Received : 07-07-2024

Accepted : 21-08-2024


Article Metrics


View Article As

 


Downlaod Files